Showing posts with label Circulating tumor cells. Show all posts
Showing posts with label Circulating tumor cells. Show all posts
Thursday, March 14, 2013
Thursday, February 28, 2013
Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer
Circulating tumor cells as a surrogate marker fo... [Br J Cancer. 2013] - PubMed - NCBI
Background:This study was aimed to detect post-chemotherapeutic circulating tumour cells (CTCs) in stage III colon cancer patients and identify those who were at high risk of relapse.Methods:We used human telomerase reverse transcriptase, cytokeratin-19, cytokeratin-20, and carcinoembryonic antigen (CEA) as the biomarkers to detect CTCs in 90 stage III colon cancer patients undergoing curative resection followed by mFOLFOX chemotherapy.Results:Post-chemotherapeutic relapse occurred in 30 (33.3%) patients. By univariate analysis and multivariate proportional hazards regression analysis, perineural invasion (hazard ratio (HR): 2.752; 95% confidence interval (CI): 1.026-7.381), high post-chemotherapeutic serum CEA levels (HR: 2.895; 95% CI: 1.143-7.333) and persistent presence of post-chemotherapeutic CTCs (HR: 6.273; 95% CI: 2.442-16.117) were independent predictors of post-chemotherapeutic relapse. In addition, the persistent presence of post-chemotherapeutic CTCs strongly correlated with reduced disease-free survival and overall survival. Accuracy of detecting relapse in post-chemotherapeutic stage III colon cancer patients by analysing the persistent presence of post-chemotherapeutic CTCs was higher than that by post-chemotherapeutic CEA levels (odds ratio: 50.091 vs 5.211).Conclusion:The persistent presence of post-chemotherapeutic CTCs is a potential powerful surrogate marker for determining clinical outcome in stage III colon cancer patients receiving adjuvant mFOLFOX chemotherapy.British Journal of Cancer advance online publication, 19 February 2013; doi:10.1038/bjc.2012.595 www.bjcancer.com.
Background:This study was aimed to detect post-chemotherapeutic circulating tumour cells (CTCs) in stage III colon cancer patients and identify those who were at high risk of relapse.Methods:We used human telomerase reverse transcriptase, cytokeratin-19, cytokeratin-20, and carcinoembryonic antigen (CEA) as the biomarkers to detect CTCs in 90 stage III colon cancer patients undergoing curative resection followed by mFOLFOX chemotherapy.Results:Post-chemotherapeutic relapse occurred in 30 (33.3%) patients. By univariate analysis and multivariate proportional hazards regression analysis, perineural invasion (hazard ratio (HR): 2.752; 95% confidence interval (CI): 1.026-7.381), high post-chemotherapeutic serum CEA levels (HR: 2.895; 95% CI: 1.143-7.333) and persistent presence of post-chemotherapeutic CTCs (HR: 6.273; 95% CI: 2.442-16.117) were independent predictors of post-chemotherapeutic relapse. In addition, the persistent presence of post-chemotherapeutic CTCs strongly correlated with reduced disease-free survival and overall survival. Accuracy of detecting relapse in post-chemotherapeutic stage III colon cancer patients by analysing the persistent presence of post-chemotherapeutic CTCs was higher than that by post-chemotherapeutic CEA levels (odds ratio: 50.091 vs 5.211).Conclusion:The persistent presence of post-chemotherapeutic CTCs is a potential powerful surrogate marker for determining clinical outcome in stage III colon cancer patients receiving adjuvant mFOLFOX chemotherapy.British Journal of Cancer advance online publication, 19 February 2013; doi:10.1038/bjc.2012.595 www.bjcancer.com.
Wednesday, February 20, 2013
Monday, February 18, 2013
Friday, February 8, 2013
Sunday, February 3, 2013
Thursday, January 31, 2013
Sunday, January 27, 2013
Triple Negative Breast Cancer Foundation®
Triple Negative Breast Cancer Foundation®
"To evaluate the impact of circulating tumor cells by type of breast cancer, researchers conducted a study among 486 women with metastatic breast cancer. The median age of the women was 55 years, and 18% had triple-negative breast cancer.
Overall, circulating tumor cells (at least 5 cells per 7.5 ml of blood) were detected in 42% of women. The likelihood of testing positive for circulating tumor cells did not vary substantially by type of breast cancer: circulating tumor cells were detected in 46% of women with hormone receptor-positive/HER2-negative breast cancer, 37% of women with HER2-positive breast cancer, and 36% of women with triple-negative breast cancer.
Women who tested negative for circulating tumor cells tended to have better outcomes than women who tested positive. Among women with triple-negative breast cancer, time to cancer progression was 5.8 months among women without circulating tumor cells and 3.1 months among women with circulating tumor cells. Overall survival was also better among who tested negative for circulating tumor cells.
Similar results were found among women with hormone receptor-positive/HER2-negative breast cancer: the absence of circulating tumor cells was linked with better progression-free and overall survival. Among women with HER2-positive breast cancer, the absence of circulating tumor cells was linked with better overall survival, but did not significantly affect progression-free survival.These results suggest that circulating tumor cells provide information about the prognosis of several different subtypes of metastatic breast cancer, including triple-negative breast cancer. Research in this area continues and could eventually help guide treatment decisions."
"To evaluate the impact of circulating tumor cells by type of breast cancer, researchers conducted a study among 486 women with metastatic breast cancer. The median age of the women was 55 years, and 18% had triple-negative breast cancer.
Overall, circulating tumor cells (at least 5 cells per 7.5 ml of blood) were detected in 42% of women. The likelihood of testing positive for circulating tumor cells did not vary substantially by type of breast cancer: circulating tumor cells were detected in 46% of women with hormone receptor-positive/HER2-negative breast cancer, 37% of women with HER2-positive breast cancer, and 36% of women with triple-negative breast cancer.
Women who tested negative for circulating tumor cells tended to have better outcomes than women who tested positive. Among women with triple-negative breast cancer, time to cancer progression was 5.8 months among women without circulating tumor cells and 3.1 months among women with circulating tumor cells. Overall survival was also better among who tested negative for circulating tumor cells.
Similar results were found among women with hormone receptor-positive/HER2-negative breast cancer: the absence of circulating tumor cells was linked with better progression-free and overall survival. Among women with HER2-positive breast cancer, the absence of circulating tumor cells was linked with better overall survival, but did not significantly affect progression-free survival.These results suggest that circulating tumor cells provide information about the prognosis of several different subtypes of metastatic breast cancer, including triple-negative breast cancer. Research in this area continues and could eventually help guide treatment decisions."
Friday, January 25, 2013
Thursday, January 24, 2013
Wednesday, January 23, 2013
Tuesday, January 22, 2013
Wednesday, January 16, 2013
Tuesday, January 15, 2013
Friday, January 11, 2013
Thursday, January 10, 2013
Sunday, December 30, 2012
Subscribe to:
Posts (Atom)